Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
25/09/2024 | 09:30 | PR Newswire (US) | Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 | NASDAQ:NKTR | Nektar Therapeutics |
03/09/2024 | 15:00 | PR Newswire (US) | Nektar Management to Present at Upcoming Investor Conferences | NASDAQ:NKTR | Nektar Therapeutics |
21/08/2024 | 03:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NKTR | Nektar Therapeutics |
19/08/2024 | 22:13 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:NKTR | Nektar Therapeutics |
08/08/2024 | 22:20 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NKTR | Nektar Therapeutics |
08/08/2024 | 22:15 | PR Newswire (US) | Nektar Therapeutics Reports Second Quarter 2024 Financial Results | NASDAQ:NKTR | Nektar Therapeutics |
02/08/2024 | 00:00 | PR Newswire (US) | Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets | NASDAQ:NKTR | Nektar Therapeutics |
12/06/2024 | 15:30 | PR Newswire (US) | Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 | NASDAQ:NKTR | Nektar Therapeutics |
06/06/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:NKTR | Nektar Therapeutics |
05/06/2024 | 23:30 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:NKTR | Nektar Therapeutics |
28/05/2024 | 22:51 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:NKTR | Nektar Therapeutics |
09/05/2024 | 22:15 | PR Newswire (US) | Nektar Therapeutics Reports First Quarter 2024 Financial Results | NASDAQ:NKTR | Nektar Therapeutics |
03/05/2024 | 00:00 | PR Newswire (US) | Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets | NASDAQ:NKTR | Nektar Therapeutics |
22/03/2024 | 19:00 | PR Newswire (US) | Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference | NASDAQ:NKTR | Nektar Therapeutics |
05/03/2024 | 23:11 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:NKTR | Nektar Therapeutics |
05/03/2024 | 15:00 | PR Newswire (US) | Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata | NASDAQ:NKTR | Nektar Therapeutics |
04/03/2024 | 22:15 | PR Newswire (US) | Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results | NASDAQ:NKTR | Nektar Therapeutics |
04/03/2024 | 14:30 | PR Newswire (US) | Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX | NASDAQ:NKTR | Nektar Therapeutics |
28/02/2024 | 00:00 | PR Newswire (US) | Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference | NASDAQ:NKTR | Nektar Therapeutics |
27/02/2024 | 00:00 | PR Newswire (US) | Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets | NASDAQ:NKTR | Nektar Therapeutics |
14/02/2024 | 23:03 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:NKTR | Nektar Therapeutics |
04/01/2024 | 00:00 | PR Newswire (US) | Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA | NASDAQ:NKTR | Nektar Therapeutics |
12/12/2023 | 00:00 | PR Newswire (US) | Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting | NASDAQ:NKTR | Nektar Therapeutics |
07/11/2023 | 22:15 | PR Newswire (US) | Nektar Therapeutics Reports Third Quarter 2023 Financial Results | NASDAQ:NKTR | Nektar Therapeutics |
31/10/2023 | 23:00 | PR Newswire (US) | Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets | NASDAQ:NKTR | Nektar Therapeutics |
13/10/2023 | 14:30 | PR Newswire (US) | Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress | NASDAQ:NKTR | Nektar Therapeutics |
02/10/2023 | 15:00 | PR Newswire (US) | Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy | NASDAQ:NKTR | Nektar Therapeutics |
27/09/2023 | 15:00 | PR Newswire (US) | Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer | NASDAQ:NKTR | Nektar Therapeutics |
13/09/2023 | 15:00 | PR Newswire (US) | Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis | NASDAQ:NKTR | Nektar Therapeutics |
07/09/2023 | 00:00 | PR Newswire (US) | Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th | NASDAQ:NKTR | Nektar Therapeutics |